Index RUT
P/E -
EPS (ttm) -1.63
Insider Own 12.59%
Shs Outstand 98.63M
Perf Week -1.21%
Market Cap 728.42M
Forward P/E -
EPS next Y -1.75
Insider Trans -0.27%
Shs Float 86.74M
Perf Month -1.61%
Income -160.93M
PEG -
EPS next Q -0.48
Inst Own 103.90%
Short Float 15.17%
Perf Quarter 97.31%
Sales 63.53M
P/S 11.47
EPS this Y -17.51%
Inst Trans -2.82%
Short Ratio 4.52
Perf Half Y 263.37%
Book/sh 3.74
P/B 1.96
EPS next Y 9.20%
ROA -26.56%
Short Interest 13.16M
Perf Year 33.94%
Cash/sh 3.18
P/C 2.31
EPS next 5Y -
ROE -37.76%
52W Range 1.63 - 8.83
Perf YTD 96.26%
Dividend Est. -
P/FCF -
EPS past 5Y -6.65%
ROI -34.55%
52W High -16.87%
Beta 1.66
Dividend TTM -
Quick Ratio 8.48
Sales past 5Y 87.14%
Gross Margin 71.22%
52W Low 350.31%
ATR (14) 0.66
Dividend Ex-Date -
Current Ratio 8.48
EPS Y/Y TTM 43.83%
Oper. Margin -299.86%
RSI (14) 53.44
Volatility 8.94% 9.52%
Employees 181
Debt/Eq 0.28
Sales Y/Y TTM -34.03%
Profit Margin -253.30%
Recom 2.58
Target Price 7.64
Option/Short Yes / Yes
LT Debt/Eq 0.26
EPS Q/Q 22.82%
Payout -
Rel Volume 0.00
Prev Close 7.34
Sales Surprise 8.97%
EPS Surprise 13.83%
Sales Q/Q -96.22%
Earnings Feb 26 AMC
Avg Volume 2.91M
Price 7.34
SMA20 -0.66%
SMA50 11.62%
SMA200 83.08%
Trades
Volume 0
Change 0.00%
Date
Action
Analyst
Rating Change
Price Target Change
Mar-27-23 Resumed
Wells Fargo
Equal Weight
$6
Jan-24-23 Downgrade
H.C. Wainwright
Buy → Neutral
$115 → $7
Jan-06-23 Downgrade
Wedbush
Outperform → Neutral
$42 → $7
Jan-06-23 Downgrade
Truist
Buy → Hold
$46 → $7
Jan-06-23 Downgrade
Stifel
Buy → Hold
$107 → $5.30
Jan-06-23 Downgrade
Piper Sandler
Overweight → Neutral
$71 → $12
Jan-06-23 Downgrade
Cowen
Outperform → Market Perform
Jan-06-23 Downgrade
BofA Securities
Buy → Underperform
$72 → $4
Jan-06-23 Downgrade
BMO Capital Markets
Outperform → Market Perform
$20 → $7
Jan-03-23 Downgrade
Guggenheim
Buy → Neutral
Dec-22-22 Downgrade
Oppenheimer
Outperform → Perform
Dec-15-22 Initiated
Goldman
Sell
$10
Nov-04-22 Resumed
Cantor Fitzgerald
Overweight
$98 → $45
Oct-10-22 Initiated
Canaccord Genuity
Buy
$42
Aug-18-22 Resumed
Wells Fargo
Overweight
$90
Jul-28-22 Initiated
Needham
Hold
Jul-11-22 Upgrade
BMO Capital Markets
Market Perform → Outperform
$50 → $47
Jun-03-22 Initiated
Robert W. Baird
Neutral
$28
Feb-11-22 Resumed
BMO Capital Markets
Market Perform
$50
Dec-15-21 Upgrade
Wedbush
Neutral → Outperform
Show Previous Ratings
Mar-27-24 11:30AM
Mar-19-24 08:44AM
Mar-05-24 04:01PM
Mar-01-24 08:09AM
08:00AM
09:16AM
Loading…
Feb-27-24 09:16AM
08:07AM
(Thomson Reuters StreetEvents)
Feb-26-24 05:10PM
04:35PM
04:08PM
(Associated Press Finance)
04:01PM
Feb-21-24 09:21AM
Feb-19-24 10:00AM
Feb-15-24 08:00AM
Feb-02-24 04:01PM
07:54AM
Loading…
Jan-30-24 07:54AM
Jan-29-24 02:53PM
Jan-08-24 08:00AM
Dec-22-23 12:00PM
Dec-18-23 02:58PM
Dec-13-23 05:00PM
Dec-08-23 11:30AM
Nov-09-23 01:18PM
Nov-08-23 06:18PM
04:08PM
(Associated Press Finance)
04:01PM
Oct-25-23 08:00AM
Sep-15-23 06:01AM
Sep-07-23 11:30AM
Aug-31-23 08:00AM
07:30AM
Loading…
Aug-29-23 07:30AM
Aug-09-23 12:12PM
11:04AM
(Thomson Reuters StreetEvents)
Aug-08-23 05:15PM
04:11PM
(Associated Press Finance)
04:01PM
Jul-28-23 08:00AM
Jul-22-23 08:35AM
Jul-01-23 10:33AM
Jun-16-23 03:53PM
Jun-14-23 06:42AM
Jun-08-23 11:30AM
Jun-07-23 11:30AM
Jun-04-23 08:27AM
Jun-02-23 11:31AM
May-31-23 08:00AM
May-25-23 10:49AM
May-08-23 06:05AM
May-04-23 11:59AM
11:22AM
(Thomson Reuters StreetEvents)
May-03-23 05:15PM
04:11PM
04:01PM
12:00PM
Apr-27-23 10:03AM
Apr-26-23 10:02AM
Apr-24-23 08:00AM
Apr-12-23 07:20AM
Mar-30-23 11:30AM
Mar-27-23 09:00AM
Mar-03-23 04:01PM
Mar-02-23 09:18PM
05:30AM
Mar-01-23 09:59AM
Feb-28-23 05:15PM
04:01PM
Feb-27-23 09:31AM
Feb-13-23 08:00AM
Feb-06-23 09:55AM
Feb-02-23 09:46AM
Jan-30-23 07:33AM
Jan-28-23 01:30PM
Jan-19-23 09:35AM
Jan-17-23 06:27AM
Jan-06-23 01:55PM
10:54AM
10:27AM
08:49AM
Jan-05-23 05:00PM
07:40AM
Jan-03-23 09:35AM
Jan-02-23 08:39AM
Dec-13-22 08:00AM
Dec-12-22 07:30AM
Dec-10-22 02:46PM
10:00AM
Nov-09-22 03:55PM
Nov-07-22 08:00AM
Nov-04-22 04:01PM
Nov-03-22 05:35PM
04:01PM
09:00AM
Nov-01-22 10:01AM
Oct-31-22 08:49AM
Oct-27-22 10:03AM
Oct-24-22 04:01PM
Oct-16-22 08:41AM
Oct-05-22 08:00AM
Sep-15-22 11:54AM
Sep-02-22 11:31AM
Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Dulac Edward J III Chief Financial Officer Mar 04 '24 Sale 7.77 2,447 19,013 101,479 Mar 05 04:24 PM Dulac Edward J III Chief Financial Officer Jan 29 '24 Sale 5.00 1,849 9,245 103,926 Jan 30 04:01 PM Wolchko J Scott President and CEO Jan 09 '24 Sale 4.37 14,391 62,889 371,248 Jan 10 04:29 PM Valamehr Bahram Chief R&D Officer Jan 09 '24 Sale 4.38 11,271 49,367 158,069 Jan 10 04:30 PM TAHL CINDY General Counsel and Secretary Jan 09 '24 Sale 4.37 10,874 47,519 142,361 Jan 10 04:30 PM Dulac Edward J III Chief Financial Officer Jan 09 '24 Sale 4.37 7,028 30,712 105,775 Jan 10 04:29 PM Dulac Edward J III Chief Financial Officer Jan 02 '24 Sale 3.66 5,182 18,966 112,803 Jan 03 04:03 PM Redmile Group, LLC Director Dec 26 '23 Buy 3.72 44,630 166,024 13,180,388 Dec 28 09:30 PM Dulac Edward J III Chief Financial Officer Dec 18 '23 Sale 3.50 1,585 5,548 117,985 Dec 19 04:01 PM TAHL CINDY General Counsel and Secretary Nov 09 '23 Sale 2.40 24,363 58,471 153,235 Nov 13 04:01 PM Dulac Edward J III Chief Financial Officer Aug 18 '23 Sale 2.80 4,718 13,210 119,570 Aug 21 04:02 PM Xu Yuan Director Aug 04 '23 Sale 3.71 632 2,345 9,302 Aug 07 04:01 PM Dulac Edward J III Chief Financial Officer Jul 05 '23 Sale 4.83 5,182 25,029 124,288 Jul 06 05:18 PM Powl Brian T. Chief Commercial Officer Jul 05 '23 Sale 4.87 3,854 18,769 41,146 Jul 06 05:19 PM Xu Yuan Director Jun 14 '23 Sale 5.58 3,460 19,307 9,934 Jun 15 04:05 PM Redmile Group, LLC Director Apr 21 '23 Buy 6.18 256,639 1,586,029 13,135,758 Apr 21 09:55 PM Redmile Group, LLC Director Apr 20 '23 Buy 5.99 20,000 119,800 12,879,119 Apr 21 09:55 PM Chu Yu-Waye Chief Medical Officer Apr 18 '23 Sale 6.57 2,532 16,648 140,676 Apr 19 04:07 PM Redmile Group, LLC Director Apr 14 '23 Buy 6.00 25,700 154,200 12,859,119 Apr 17 09:30 PM Redmile Group, LLC Director Apr 14 '23 Sale 5.84 302,339 1,765,660 12,833,419 Apr 17 09:30 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite